Page last updated: 2024-11-05

dimethyl succinate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Dimethyl succinate is a diester of succinic acid, with the formula C6H10O4. It is a colorless liquid with a sweet odor. It is used as a plasticizer, a solvent, and an intermediate in the synthesis of other chemicals. Dimethyl succinate can be synthesized by the esterification of succinic acid with methanol. It is also a component of some biofuels. Dimethyl succinate is biodegradable and non-toxic, making it a more environmentally friendly alternative to some other plasticizers and solvents. It is also being studied as a potential precursor to bio-based polymers and other valuable chemicals. '

dimethyl succinate: potent insulin secretagogue [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID7820
CHEMBL ID556489
CHEBI ID165393
SCHEMBL ID10213
MeSH IDM0158324

Synonyms (68)

Synonym
LS-13155
butanedioic acid, dimethyl ester
succinic acid, dimethyl ester
nsc-52209
dimethyl butanedioate
nsc52209
methyl succinate
nsc 52209
hsdb 5370
ccris 4803
ai3-02480
fema no. 2396
methyl butanedioate
einecs 203-419-9
106-65-0
inchi=1/c6h10o4/c1-9-5(7)3-4-6(8)10-2/h3-4h2,1-2h
dimethyl succinate
NCGC00091530-01
dimethylsuccinate
dimethyl succinate, 98%, fg
dbe-4 dibasic ester, 98%
dbe-4 dibasic ester
smr001253742
MLS002454400
AKOS000269071
CHEBI:165393
succinic acid dimethyl ester
CHEMBL556489
NCGC00091530-03
NCGC00091530-02
tox21_202189
tox21_300350
cas-106-65-0
NCGC00254517-01
dtxsid5025152 ,
NCGC00259738-01
dtxcid005152
butanedioic acid dimethyl ester
HMS2270G19
unii-914i2127jr
ec 203-419-9
914i2127jr ,
butanedioic acid, 1,4-dimethyl ester
FT-0621972
dimethyl succinate [fhfi]
succinic acid dimethyl ester [mi]
dimethyl succinate [hsdb]
dimethyl succinate [inci]
dimethyl succinate [fcc]
SCHEMBL10213
ch3oc(o)ch2ch2c(o)och3
dimethyl ester of succinic acid
dbe-4
STL481902
1,4-dimethyl butanedioate
J-001620
F1905-7126
dimethyl succinate, analytical standard
mfcd00008466
dimethyl succinate, purum, >=98.0% (gc)
dimethyl succinate, vetec(tm) reagent grade, 98%
succinic acid-dimethyl ester
fema 2396
dimethyl 1,4-butanedioate
Q27271375
CS-0015787
A904500
EN300-113007
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
fatty acid methyl esterA fatty acid ester that is the carboxylic ester obtained by the formal condensation of a fatty acid with methanol.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (11)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLI family zinc finger 3Homo sapiens (human)Potency25.00630.000714.592883.7951AID1259369; AID1259392
thyroid stimulating hormone receptorHomo sapiens (human)Potency0.63100.001318.074339.8107AID926; AID938
progesterone receptorHomo sapiens (human)Potency7.90770.000417.946075.1148AID1346795
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency31.48100.003041.611522,387.1992AID1159552
pregnane X nuclear receptorHomo sapiens (human)Potency55.98200.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency22.46780.000229.305416,493.5996AID743069
aryl hydrocarbon receptorHomo sapiens (human)Potency76.95880.000723.06741,258.9301AID743085
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency24.541219.739145.978464.9432AID1159509
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency70.79460.050127.073689.1251AID588590
gemininHomo sapiens (human)Potency2.37830.004611.374133.4983AID624296; AID624297
Nuclear receptor ROR-gammaHomo sapiens (human)Potency23.71010.026622.448266.8242AID651802
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (13)

Processvia Protein(s)Taxonomy
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (21)

Assay IDTitleYearJournalArticle
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1763200Inhibition of TET in human THP-1 cells assessed as reduction in 5hmc/5mc level at 50 uM incubated for 12 hrs by dot blot analysis relative to control2021Bioorganic & medicinal chemistry, 06-01, Volume: 39SAR insights into TET2 catalytic domain inhibition: Synthesis of 2-Hydroxy-4-Methylene-pentanedicarboxylates.
AID426463Inhibition of JMJD2C-mediated H3K9 demethylation in human 293T cells at 100 mM2009Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10
Synthesis and activity of N-oxalylglycine and its derivatives as Jumonji C-domain-containing histone lysine demethylase inhibitors.
AID1763199Inhibition of TET in human THP-1 cells assessed as reduction in 5hmc/5mc level at 25 uM incubated for 12 hrs by dot blot analysis relative to control2021Bioorganic & medicinal chemistry, 06-01, Volume: 39SAR insights into TET2 catalytic domain inhibition: Synthesis of 2-Hydroxy-4-Methylene-pentanedicarboxylates.
AID1763201Inhibition of TET in human THP-1 cells assessed as reduction in 5hmc/5mc level at 100 uM incubated for 12 hrs by dot blot analysis relative to control2021Bioorganic & medicinal chemistry, 06-01, Volume: 39SAR insights into TET2 catalytic domain inhibition: Synthesis of 2-Hydroxy-4-Methylene-pentanedicarboxylates.
AID426462Inhibition of JMJD2C-mediated H3K36 demethylation in human 293T cells at 100 mM2009Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10
Synthesis and activity of N-oxalylglycine and its derivatives as Jumonji C-domain-containing histone lysine demethylase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (49)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (2.04)18.7374
1990's20 (40.82)18.2507
2000's14 (28.57)29.6817
2010's11 (22.45)24.3611
2020's3 (6.12)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 44.17

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index44.17 (24.57)
Research Supply Index4.01 (2.92)
Research Growth Index6.14 (4.65)
Search Engine Demand Index61.97 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (44.17)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (3.70%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other52 (96.30%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]